1,673 results on '"McLaughlin, Peter"'
Search Results
152. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha
153. Follicular lymphoma: the case for timely intervention
154. VENTILATION-PERFUSION ABNORMALITIES IN SEVERE ASTHMA: TP 059
155. A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I–III follicular lymphoma
156. List of Contributors
157. Exploring the Limits of Preclassical Mechanics
158. Geology and Hydrogeology of St. Croix, Virgin Islands
159. Phase 2 Trial of Rituximab Plus Hyper-Cvad Alternating With Rituximab Plus Methotrexate-Cytarabine for Relapsed Or Refractory Aggressive Mantle Cell Lymphoma
160. The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats
161. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
162. Systemic administration of the adenosine A2A agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intake
163. Central vs. peripheral administration of ethanol, acetaldehyde and acetate in rats: Effects on lever pressing and response initiation
164. CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate
165. Phase 2 Study of Gemcitabine in Combination With Rituximab in Patients With Recurrent Or Refractory Hodgkin Lymphoma
166. Prevalence and Nature of Systemic Involvement and Stage at Initial Examination in Patients With Orbital and Ocular Adnexal Lymphoma
167. Meta–analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics
168. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma
169. Value of Positron Emission Tomography in Staging Ocular Adnexal Lymphomas and Evaluating Their Response to Therapy
170. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
171. Book review
172. Transcatheter Closure of Aortic Sinus to Left Atrial Fistula Caused by Erosion of Amplatzer Septal Occluder
173. Comparison between multiple behavioral effects of peripheral ethanol administration in rats: Sedation, ataxia, and bradykinesia
174. Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center
175. Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387
176. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma
177. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas
178. Effect of long flights on the cognitive performance of air crew
179. Introduction
180. High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine
181. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma
182. Follicular Lymphoma International Prognostic Index
183. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen
184. Behavioral effects of the novel cannabinoid full agonist AM 411
185. Concurrent Administration of High-Dose Rituximab Before and After Autologous Stem-Cell Transplantation for Relapsed Aggressive B-Cell Non-Hodgkinʼs Lymphomas
186. Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkinʼs Lymphoma
187. Chapter 10 Geology and hydrogeology of St. Croix, Virgin Islands
188. Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkinʼs Lymphoma
189. Nonmyeloablative Allogeneic Hematopoietic Transplantation: A Promising Salvage Therapy for Patients With Non-Hodgkinʼs Lymphoma Whose Disease Has Failed a Prior Autologous Transplantation
190. Chapter 13 Evolution of the neogene kingshill basin of St. Croix, U.S. Virgin Islands
191. Nonablative Allogeneic Stem-Cell Transplantation for Advanced/Recurrent Mantle-Cell Lymphoma
192. Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I–II Indolent Non-Hodgkin’s Lymphoma
193. Factors Predicting the Response to Rituximab in Indolent Lymphoma
194. Coarctation of the Aorta in an Adult*: Problems of Diagnosis and Management
195. Thalidomide for patients with reccurent lymphoma
196. Phase I Clinical and Pharmacology Study of Clofarabine in Patients With Solid and Hematologic Cancers
197. Update on the Activity of Rituximab/CHOP Combinations in Non-Hodgkinʼs Lymphoma
198. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated franctionation radiation therapy after chemotherapy
199. Immunotherapy for Low-Grade Non-Hodgkin Secondary Lymphoma of the Orbit
200. A pilot study of Rituximab in patients with recurrent, classic Hodgkin disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.